Fixed-duration ibrutinib + venetoclax for CLL, aryl hydrocarbon receptor in idiopathic pneumonia syndrome, and VWF propeptide and multimerization

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

🌑 Deep Space Ocean Waves | 8 Hours of Peaceful Piano with Ocean Waves & Deep Space Ambience for Healing REM Sleep 🌊 8h 56m · 20 Sep 2026 · 8 Hour Sleep Music

Commentary Box: Andrew Saville and Jason Pine discuss the Warriors finals exit, NZ Rugby's financial woes 11 min · 20 Sep 2026 · The Mike Hosking Breakfast

"It was everything we love about footy." | First Thoughts - Hawthorn vs Brisbane (21.09.26) 16 min · 20 Sep 2026 · SEN Breakfast

What does global leadership on AI look like? 11 min · 20 Sep 2026 · Consider This from NPR

Full Show Podcast: 21 September 2026 1h 30m · 20 Sep 2026 · The Mike Hosking Breakfast

MORNING TEA: Emily In Paris Comes To An End & The Channing Tatum Burner Account Chaos 8 min · 20 Sep 2026 · The Spill

Report any issue

Source

Recorded02 Jun 2022

Publisherfeeds.transistor.fm ↗

Handlerec:11742084

Show notes

In this week's episode, we discuss results from the international phase 2 CAPTIVATE study showing that in patients with treatment-naive CLL, fixed-dose ibrutinib plus venetoclax yields deep and durable responses and promising progression-free survival. We’ll also explore data that show that aryl hydrocarbon receptor is a critical inflammation checkpoint in the lung epithelium—a finding that may have therapeutic implications for idiopathic pneumonia syndrome. Lastly, we’ll review new insights into the role of von Willebrand Factor propeptide in facilitating multimer formation, shedding light on a potential novel treatment approach for type 2a von Willebrand disease.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in